Jounce Therapeutics Inc. plans to raise approximately $101.8 million in its IPO of 6,365,000 shares.
The clinical-stage immunotherapy company priced its offering at $16 apiece and offered underwriters a 30-day option to purchase up to an additional 954,750 of the shares offered.
The shares are scheduled to begin trading on Nasdaq on Jan. 27 under the JNCE ticker symbol.
J.P. Morgan and Cowen and Co. are acting as joint book-running managers for the offering. Meanwhile, Wells Fargo Securities is acting as lead manager and Baird is acting as a co-manager for the offering.